Susquehanna International Group’s Bright Minds Biosciences DRUG Stock Holding History

Susquehanna International Group’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$229K	Buy	+3,141	New	+$253K	﹤0.01%	11442

Other funds holding DRUG

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group's DRUG Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 3,141 shares worth $229K. The stake represents ﹤0.01% of the portfolio and ranks #11442 among its holdings.

94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

Susquehanna International Group held 3,141 shares of Bright Minds Biosciences worth $229K as of Q1 2026.
Bright Minds Biosciences was a new Susquehanna International Group position in Q1 2026.
Bright Minds Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11442 holding.
94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.